GEODON
LOE ApproachingNDAINTRAMUSCULARPOWDER
Approved
Jun 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
GEODON by Viatris is 2 (d 2 ) and serotonin type 2 (5ht 2 ) antagonism. Approved for schizophrenia in adults [see ], acute agitation in schizophrenic adult patients for whom treatment with ziprasidone is appropriate, need intramuscular antipsychotic medication for rapid control of agitation [see ]. First approved in 2002.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEODON (ziprasidone mesylate) is an atypical antipsychotic administered via intramuscular injection that works through dopamine D2 and serotonin 5HT2 receptor antagonism. It is indicated for acute agitation in patients with schizophrenia and bipolar disorder, addressing psychotic and behavioral symptoms through dual monoamine pathway inhibition.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team downsizing or reallocation of resources.
Mechanism of Action
2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.
Clinical Trials (7)
Geodon in Weight Loss Study for Bipolar Disorders
Started Jan 2007
25 enrolled
Bipolar Disorder
Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Started Dec 2006
73 enrolled
Bipolar DisorderBipolar DepressionDepression
A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.
Started Feb 2006
392 enrolled
Bipolar Disorder
A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression
Started Jul 2005
536 enrolled
Bipolar Disorder
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
Started Feb 2005
30 enrolled
Bipolar II DisorderMajor Depressive Episode
Worked on GEODON at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.